



The Role of Antioxidants in Managing Diabetes-Associated Anemia: Current Evidence and Future Directions

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, which is often accompanied by complications such as anemia. Diabetes-associated anemia (DAA) arises due to multifactorial mechanisms, including oxidative stress, inflammation, erythropoietin deficiency, and iron metabolism dysregulation. Recent studies highlight the role of oxidative stress in exacerbating DAA, suggesting that antioxidants may offer a therapeutic advantage. This review explores the pathophysiology of DAA, emphasizing the impact of oxidative stress and the potential benefits of antioxidants in its management. We examine current evidence on the role of natural and synthetic antioxidants, such as vitamins C and E, polyphenols, flavonoids, and coenzyme Q10, in mitigating DAA. Furthermore, we discuss potential clinical applications and future research directions in antioxidant therapy for diabetic anemia. The findings suggest that targeted antioxidant strategies could serve as adjunctive therapies in diabetes management, improving erythropoiesis and overall patient outcomes.

Keywords: Diabetes-associated anemia, oxidative stress, antioxidants, erythropoiesis, polyphenols

INTRODUCTION

Diabetes mellitus (DM) is a global health crisis, affecting millions of individuals worldwide [1–3]. This chronic metabolic disorder, characterized by persistent hyperglycemia due to defects in insulin secretion or action, is associated with a wide range of complications that can affect various organs and systems [3]. Among these complications, cardiovascular diseases, neuropathy, nephropathy, and anemia are among the most common and severe. Diabetes-associated anemia (DAA) has emerged as a significant concern, particularly in patients with chronic kidney disease (CKD), a frequent comorbidity in individuals with diabetes [4, 5]. DAA is marked by reduced hemoglobin levels and impaired red blood cell (RBC) production, contributing to diminished quality of life and, in some cases, increased mortality.

The pathogenesis of DAA is multifactorial, involving complex interactions between oxidative stress, inflammation, reduced erythropoietin production, and altered iron metabolism. One of the main contributors to DAA is kidney dysfunction, which leads to reduced erythropoietin (EPO) production, a hormone essential for RBC production [6–8]. Additionally, oxidative stress and inflammation, both hallmarks of diabetes, exacerbate the condition by impairing erythropoiesis and promoting RBC destruction. Iron metabolism is also disrupted in DAA, with inflammation-induced changes in iron regulation further complicating the anemia [9, 10].

Given the growing prevalence of diabetes and its associated complications, novel treatment strategies are urgently needed to manage DAA effectively. Antioxidants, which counteract oxidative stress and reduce inflammation, have gained attention as potential therapeutic agents for DAA. These compounds offer a promising avenue for addressing the underlying mechanisms of DAA, particularly by mitigating oxidative damage and improving iron homeostasis. This review aims to provide a comprehensive overview of the role of antioxidants in managing DAA, summarizing the current evidence and exploring future research directions to enhance treatment strategies for this increasingly prevalent complication.

Pathophysiology of Diabetes-Associated Anemia

Diabetic anemia (DAA) is influenced by several interconnected and complex mechanisms that significantly impact the pathophysiology of the condition. These mechanisms include:

Oxidative Stress: Persistent hyperglycemia in diabetes results in the overproduction of reactive oxygen species (ROS), which are highly reactive molecules that damage cellular structures. This oxidative stress leads to the destruction of red blood cells (RBCs) by damaging their membranes, proteins, and lipids. The excessive ROS generation impairs erythropoiesis, the process of RBC production, and shortens the lifespan of circulating RBCs. The decreased RBC survival further contributes to the development of anemia in diabetic patients [11–13].

Inflammation: Chronic low-grade inflammation is a hallmark of diabetes and is involved in the development of diabetic anemia. Inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukins (IL-6), and C-reactive protein (CRP) interfere with the normal function of the bone marrow and suppress the production of erythropoietin (EPO), a hormone that stimulates RBC production [14, 15]. Additionally, chronic inflammation disrupts iron homeostasis by affecting the availability and utilization of iron, further exacerbating the development of anemia. The combined effect of inflammation and oxidative stress results in a vicious cycle that worsens the anemic state. [15]

Erythropoietin Deficiency: Erythropoietin (EPO) is a key hormone produced by the kidneys that regulates RBC production in the bone marrow. In diabetic individuals, particularly those with diabetic nephropathy, kidney function is compromised, leading to a reduction in erythropoietin synthesis [16–18]. The deficiency in erythropoietin hampers the production of RBCs, contributing to the onset and progression of anemia in diabetic patients. Additionally, low EPO levels fail to compensate for the increased RBC destruction caused by oxidative stress and inflammation.

Iron Metabolism Dysregulation: Diabetes also affects various aspects of iron metabolism, including iron absorption, transport, and storage. In diabetic individuals, there is often an imbalance between iron availability and RBC production [19–21]. Despite normal or even elevated iron stores in the body, the inefficient use of iron by the bone marrow leads to a functional iron deficiency. This occurs because the inflammatory cytokines produced during diabetes interfere with iron mobilization from storage sites, impairing the delivery of iron to the bone marrow for hemoglobin synthesis. As a result, iron is not adequately utilized in the production of RBCs, contributing to the development of anemia. Overall, the development of diabetic anemia is the result of a complex interplay between oxidative stress, inflammation, erythropoietin deficiency, and dysregulated iron metabolism [22]. Each of these mechanisms exacerbates the others, leading to a progressive decline in RBC production and an increased risk of anemia in individuals with diabetes.

The Role of Antioxidants in Diabetes-Associated Anemia Mechanisms of Antioxidant Action

Antioxidants play a crucial role in protecting cells and tissues from oxidative damage by neutralizing reactive oxygen species (ROS) and reducing oxidative stress. In the context of disorders such as drug-induced anemia (DAA), antioxidants have proven to be beneficial in several key mechanisms [23]. Reactive oxygen species, which are highly reactive molecules generated during metabolic processes or as a consequence of drug-induced toxicity, can damage cellular components, including lipids, proteins, and DNA. When these ROS accumulate in excessive amounts, they lead to oxidative stress, a condition that triggers a cascade of detrimental effects, including inflammation, cellular dysfunction, and impaired red blood cell (RBC) function. Antioxidants counteract this damage by neutralizing ROS through various biochemical pathways, thus reducing oxidative stress and maintaining cellular homeostasis [24, 25]. This protective mechanism is particularly significant in DAA, where oxidative damage to RBCs is a primary factor contributing to the progression of anemia.

One of the critical benefits of antioxidants in DAA is their ability to protect RBCs from oxidative damage. Red blood cells, which are responsible for oxygen transport throughout the body, are highly vulnerable to oxidative stress due to their high hemoglobin content and constant exposure to ROS [26]. The integrity of RBC membranes and the functionality of hemoglobin can be compromised by oxidative stress, leading to hemolysis, impaired oxygen transport, and anemia. Antioxidants, such as vitamins C and E, glutathione, and various enzymatic antioxidants, help preserve RBC integrity by scavenging ROS and reducing lipid peroxidation in the membrane, thus preventing the premature destruction of RBCs. [27]

In addition to protecting RBCs, antioxidants also enhance the production of erythropoietin (EPO), a hormone primarily responsible for stimulating RBC production in the bone marrow. EPO production is often compromised during oxidative stress and inflammation [28]. Antioxidants help mitigate oxidative damage to the kidneys, where EPO is produced, thereby promoting its synthesis and supporting the process of erythropoiesis. By increasing EPO levels, antioxidants contribute to improved RBC production, which is particularly beneficial in individuals suffering from DAA, where inadequate RBC production exacerbates anemia [28].

Furthermore, antioxidants play a pivotal role in modulating inflammatory pathways. Chronic inflammation is a hallmark of many forms of anemia, including DAA, and it exacerbates the harmful effects of oxidative stress. Antioxidants help reduce the levels of pro-inflammatory cytokines, such as TNF- α , IL-1, and IL-6, that are often elevated in inflammatory conditions. By inhibiting the activation of inflammatory pathways, antioxidants not

only reduce inflammation but also prevent the further oxidative damage to RBCs and other tissues, thus alleviating the symptoms associated with DAA.

Another vital benefit of antioxidants in DAA is their ability to improve iron homeostasis. Iron is essential for RBC production, but its dysregulation during oxidative stress can contribute to iron deficiency or overload [29]. Antioxidants help modulate iron metabolism by enhancing the activity of proteins involved in iron absorption and transport, ensuring adequate iron availability for erythropoiesis. Moreover, antioxidants can mitigate the adverse effects of free iron, which, in the presence of ROS, can lead to the generation of more oxidative species and further tissue damage. By improving iron homeostasis, antioxidants support the body's ability to produce healthy RBCs and maintain optimal oxygen-carrying capacity. In sum, antioxidants offer multiple protective mechanisms in the context of DAA, including the prevention of oxidative damage to RBCs, enhancement of erythropoietin production, reduction of inflammatory cytokines, and improvement of iron homeostasis. Their role in mitigating oxidative stress and inflammation highlights their potential as therapeutic agents in managing and alleviating the symptoms of drug-induced anemia.

Natural and Synthetic Antioxidants in DAA Management

Vitamin C and Vitamin E are essential antioxidants that play vital roles in protecting cells from oxidative damage, which is crucial in managing various health conditions, including diabetes [30]. Vitamin C, a water-soluble antioxidant, has the ability to scavenge reactive oxygen species (ROS) in the aqueous compartments of the body [31]. By neutralizing ROS, Vitamin C helps reduce oxidative stress, a condition that can exacerbate diabetes-related complications such as cardiovascular disease and diabetic retinopathy [31]. Additionally, Vitamin C enhances the absorption of non-heme iron, a vital nutrient for the synthesis of hemoglobin, the protein responsible for oxygen transport in red blood cells (RBCs). This improvement in iron absorption supports the body's ability to produce healthy RBCs and improve overall blood oxygen-carrying capacity [32,33,34,35,36]. Vitamin E, on the other hand, is a lipid-soluble antioxidant that protects cell membranes from lipid peroxidation, a damaging process in which ROS attack fatty acids in cellular membranes. In the context of RBCs, lipid peroxidation can lead to membrane instability and reduced RBC lifespan. By preventing this, Vitamin E ensures the integrity and longevity of RBCs, which is particularly important in individuals with diabetes, who are prone to increased oxidative stress and RBC damage [37,38,39,40]. Together, Vitamin C and Vitamin E work synergistically to reduce oxidative damage and support RBC function, playing an important role in maintaining optimal erythropoiesis and preventing hemolysis in diabetic individuals.

Polyphenols and flavonoids, plant-derived compounds found in a variety of fruits, vegetables, and herbs, offer potent antioxidant and anti-inflammatory benefits. Notable polyphenols such as quercetin, resveratrol, and curcumin have been extensively studied for their health-promoting effects, particularly in the context of diabetes [41,42,43,44]. These compounds exhibit strong antioxidant activity, neutralizing ROS and thus reducing oxidative stress, which is a major contributor to the pathophysiology of diabetes. In addition to their antioxidant properties, polyphenols like quercetin and resveratrol have been shown to enhance erythropoiesis, the process of RBC production, by improving the function of erythroid progenitor cells. This can be particularly beneficial in diabetic individuals, whose chronic hyperglycemia and inflammation can impair normal erythropoiesis [34]. Polyphenols also help reduce hemolysis, the premature destruction of RBCs, which can be a common issue in individuals with oxidative stress. Curcumin, another potent polyphenol, has been shown to modulate inflammatory pathways, further supporting RBC health and reducing the risk of anemia, a common complication in diabetic patients. The combined antioxidant and anti-inflammatory effects of polyphenols contribute significantly to improving overall RBC function and reducing the oxidative burden that exacerbates diabetic complications [45,46].

Coenzyme Q10 (CoQ10) is an essential component of the mitochondrial electron transport chain, where it plays a pivotal role in ATP production, the energy currency of cells. As an endogenous antioxidant, CoQ10 helps protect cells from oxidative damage by neutralizing ROS generated during cellular respiration. This function is particularly important for cells with high energy demands, such as RBCs, which rely heavily on mitochondrial energy production for maintaining their membrane integrity and optimal function. Studies have shown that CoQ10 supplementation can improve RBC function in individuals with diabetes, potentially enhancing hemoglobin levels and overall oxygen transport capacity. Diabetic individuals often experience reduced CoQ10 levels, which may exacerbate oxidative stress and impair cellular energy production, further contributing to the dysfunction of RBCs. By restoring CoQ10 levels, supplementation may help mitigate these effects and support healthy RBC function, which is critical in preventing anemia and improving overall circulatory health in diabetic patients.

Alpha-lipoic acid (ALA) is another powerful antioxidant that has garnered attention for its ability to reduce oxidative stress and improve glucose metabolism in diabetic individuals. ALA is unique in its dual solubility, as it is both water- and fat-soluble, allowing it to act in various cellular compartments. This characteristic enables ALA to reduce oxidative stress across a wide range of tissues, including the endothelium, where it can improve vascular function. The improvement in endothelial function is particularly beneficial for erythropoiesis, as the endothelium plays a key role in regulating the release of growth factors that stimulate RBC production. By

reducing oxidative damage to the endothelium and improving blood vessel health, ALA indirectly supports erythropoiesis and RBC function. Moreover, ALA has been shown to improve insulin sensitivity, which can have a positive effect on glucose metabolism and prevent the complications associated with diabetes, including impaired RBC production and function. In summary, ALA's antioxidant properties and its impact on glucose metabolism and endothelial function make it a valuable supplement for improving RBC health and supporting erythropoiesis in diabetic individuals.

Current Evidence on Antioxidant Therapy in DAA

Several clinical and preclinical studies have highlighted the potential of antioxidants in managing diabetes-related anemia (DAA). A randomized controlled trial investigated the effects of vitamin C and E supplementation in diabetic patients and found that it significantly improved hemoglobin levels while reducing markers of oxidative stress[35]. These antioxidants are known to neutralize free radicals, which can damage red blood cells (RBCs) in diabetic individuals. The reduction in oxidative stress likely contributed to the improvement in hemoglobin synthesis and overall blood health, suggesting that antioxidant supplementation may be a valuable therapeutic strategy in managing DAA. Such findings emphasize the role of antioxidants in mitigating the detrimental effects of diabetes on RBCs, improving oxygen delivery, and supporting erythropoiesis in these patients[35].

Animal studies have further supported the beneficial effects of antioxidants in managing DAA, particularly with polyphenol-rich diets. Research conducted on diabetic rats revealed that the inclusion of polyphenols, powerful natural antioxidants, in their diet enhanced erythropoiesis and protected RBCs from oxidative damage[36]. Polyphenols have been shown to exert protective effects on RBC membranes, thereby improving their structural integrity and function. Additionally, Coenzyme Q10 (CoQ10) supplementation has been found to improve RBC deformability and oxygen transport in diabetic rats, offering further evidence of the critical role antioxidants play in managing DAA[37]. CoQ10 is involved in cellular energy production, and its supplementation appears to mitigate the impaired RBC function commonly seen in diabetes, thus improving overall circulatory health. Together, these studies provide compelling evidence for the potential of antioxidants as effective interventions for improving RBC function and alleviating DAA in diabetic individuals[37].

Future Directions and Clinical Implications

Despite promising findings, several gaps remain in antioxidant-based therapies for DAA:

Optimal Dosage and Formulations: Further studies are needed to determine the effective doses and bioavailability of antioxidants.

Long-Term Safety: While antioxidants are generally safe, excessive intake may have pro-oxidant effects.

Combination Therapies: Future research should explore synergistic effects of combining antioxidants with conventional anemia treatments (e.g., erythropoiesis-stimulating agents and iron supplements).

Personalized Medicine Approaches: Given interindividual variations in oxidative stress levels, tailored antioxidant therapies may enhance therapeutic outcomes in DAA.

CONCLUSION

Diabetes-associated anemia is a significant complication of diabetes, driven largely by oxidative stress and inflammation. Antioxidants present a promising therapeutic avenue for managing DAA by mitigating oxidative damage, improving erythropoiesis, and modulating iron metabolism. While current evidence supports the role of antioxidants such as vitamin C, vitamin E, polyphenols, and CoQ10 in improving hemoglobin levels, further research is required to establish their clinical efficacy and long-term safety. Future studies should focus on optimizing antioxidant formulations and exploring personalized treatment approaches to enhance outcomes for diabetic patients with anemia.

REFERENCES

1. Agarwal, R.: Pathogenesis of Diabetic Nephropathy. In: Chronic Kidney Disease and Type 2 Diabetes. American Diabetes Association, Arlington (VA) (2021)
2. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov. Public Health*. 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>
3. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. *Nat. Prod. Commun*. 20, 1934578X251323393 (2025). <https://doi.org/10.1177/1934578X251323393>
4. Caturano, A., D'Angelo, M., Mormone, A., Russo, V., Mollica, M.P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., Monda, M., Giordano, A., Sasso, F.C.: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. *Curr. Issues Mol. Biol*. 45, 6651–6666 (2023). <https://doi.org/10.3390/cimb45080420>
5. Chen, Q., Zhao, X., Xu, Z., Liu, Y.: Endoplasmic reticulum stress mechanisms and exercise intervention in type 2 diabetes mellitus. *Biomed. Pharmacother*. 177, 117122 (2024). <https://doi.org/10.1016/j.biopha.2024.117122>

6. Hashmi, M.F., Aeddula, N.R., Shaikh, H., Rout, P.: Anemia of Chronic Kidney Disease. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
7. Harrison, A.V., Lorenzo, F.R., McClain, D.A.: Iron and the Pathophysiology of Diabetes. *Annu. Rev. Physiol.* 85, 339–362 (2023). <https://doi.org/10.1146/annurev-physiol-022522-102832>
8. Gogan, A., Potre, O., Avram, V.-F., Andor, M., Caruntu, F., Timar, B.: Cardiac Autonomic Neuropathy in Diabetes Mellitus: Pathogenesis, Epidemiology, Diagnosis and Clinical Implications: A Narrative Review. *J. Clin. Med.* 14, 671 (2025). <https://doi.org/10.3390/jcm14030671>
9. Das, S.N., Devi, A., Mohanta, B.B., Choudhury, A., Swain, A., Thatoi, P.K.: Oral versus intravenous iron therapy in iron deficiency anemia: An observational study. *J. Fam. Med. Prim. Care.* 9, 3619–3622 (2020). https://doi.org/10.4103/jfmprc.jfmprc_559_20
10. Udeozor, P.A., Ibiam, U.A., Uti, D.E., Umoru, G.U., Onwe, E.N., Mbonu, F.O., Omang, W.A., Ijoganu, S.I., Anaga, C.O., Mbah, J.O., Nwadium, S.K.: Antioxidant and Anti-Anemic Effects of Ethanol Leaf Extracts of *Mucuna poggei* and *Telfairia occidentalis* in Phenyl-Hydrazine-Induced Anemia in Wistar Albino Rats. *Ibnosina J. Med. Biomed. Sci.* 14, 116–126 (2022). <https://doi.org/10.1055/s-0042-1756684>
11. González, P., Lozano, P., Ros, G., Solano, F.: Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int. J. Mol. Sci.* 24, 9352 (2023). <https://doi.org/10.3390/ijms24119352>
12. Bhatti, J.S., Sehrawat, A., Mishra, J., Sidhu, I.S., Navik, U., Khullar, N., Kumar, S., Bhatti, G.K., Reddy, P.H.: Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. *Free Radic. Biol. Med.* 184, 114–134 (2022). <https://doi.org/10.1016/j.freeradbiomed.2022.03.019>
13. Caturano, A., D'Angelo, M., Mormone, A., Russo, V., Mollica, M.P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., Monda, M., Giordano, A., Sasso, F.C.: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. *Curr. Issues Mol. Biol.* 45, 6651–6666 (2023). <https://doi.org/10.3390/cimb45080420>
14. Tsalamandris, S., Antonopoulos, A.S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., Tousoulis, D.: The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. *Eur. Cardiol. Rev.* 14, 50–59 (2019). <https://doi.org/10.15420/ecr.2018.33.1>
15. Stanimirovic, J., Radovanovic, J., Banjac, K., Obradovic, M., Essack, M., Zafirovic, S., Gluvic, Z., Gojobori, T., Isenovic, E.R.: Role of C-Reactive Protein in Diabetic Inflammation. *Mediators Inflamm.* 2022, 3706508 (2022). <https://doi.org/10.1155/2022/3706508>
16. Antoniadou, C., Gavriilidis, E., Ritis, K., Tsilingiris, D.: Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy. *Metab. Open.* 25, 100344 (2025). <https://doi.org/10.1016/j.metop.2024.100344>
17. Bhoopalan, S.V., Huang, L.J., Weiss, M.J.: Erythropoietin regulation of red blood cell production: from bench to bedside and back. *F1000Research.* 9, F1000 Faculty Rev-1153 (2020). <https://doi.org/10.12688/f1000research.26648.1>
18. Chavez-MacGregor, M., Zhao, H., Fang, S., Srokowski, T.P., Hortobagyi, G.N., Giordano, S.H.: Complications Associated with Erythropoietin Stimulating Agents (ESAs) in Patients with Metastatic Breast Cancer: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Study. *Cancer.* 117, 3641–3649 (2011). <https://doi.org/10.1002/cncr.25972>
19. Camaschella, C., Nai, A., Silvestri, L.: Iron metabolism and iron disorders revisited in the hepcidin era. *Haematologica.* 105, 260–272 (2020). <https://doi.org/10.3324/haematol.2019.232124>
20. Conde Díez, S., de las Cuevas Allende, R., Conde García, E.: Anemia of inflammation and iron metabolism in chronic diseases. *Rev. Clínica Esp. Engl. Ed.* 224, 598–608 (2024). <https://doi.org/10.1016/j.rceng.2024.09.002>
21. Cronin, S.J.F., Woolf, C.J., Weiss, G., Penninger, J.M.: The Role of Iron Regulation in Immunometabolism and Immune-Related Disease. *Front. Mol. Biosci.* 6, 116 (2019). <https://doi.org/10.3389/fmolb.2019.00116>
22. Catapano, A., Cimmino, F., Petrella, L., Pizzella, A., D'Angelo, M., Ambrosio, K., Marino, F., Sabbatini, A., Petrelli, M., Paolini, B., Lucchin, L., Cavaliere, G., Cristino, L., Crispino, M., Trinchese, G., Mollica, M.P.: Iron metabolism and ferroptosis in health and diseases: the crucial role of mitochondria in metabolically active tissues. *J. Nutr. Biochem.* 109888 (2025). <https://doi.org/10.1016/j.jnutbio.2025.109888>
23. Caturano, A., Rocco, M., Tagliaferri, G., Piacevole, A., Nilo, D., Di Lorenzo, G., Iadicicco, I., Donnarumma, M., Galiero, R., Acierno, C., Sardu, C., Russo, V., Vetrano, E., Conte, C., Marfella, R., Rinaldi, L., Sasso, F.C.: Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications. *Antioxidants.* 14, 72 (2025). <https://doi.org/10.3390/antiox14010072>

24. Juan, C.A., Pérez de la Lastra, J.M., Plou, F.J., Pérez-Lebeña, E.: The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. *Int. J. Mol. Sci.* 22, 4642 (2021). <https://doi.org/10.3390/ijms22094642>
25. Deavall, D.G., Martin, E.A., Horner, J.M., Roberts, R.: Drug-Induced Oxidative Stress and Toxicity. *J. Toxicol.* 2012, 645460 (2012). <https://doi.org/10.1155/2012/645460>
26. Daraghme, D.N., Karaman, R.: The Redox Process in Red Blood Cells: Balancing Oxidants and Antioxidants. *Antioxidants*. 14, 36 (2024). <https://doi.org/10.3390/antiox14010036>
27. Tzounakas, V.L., Anastasiadi, A.T., Arvaniti, V.-Z., Lelli, V., Fanelli, G., Paronis, E.C., Apostolidou, A.C., Balafas, E.G., Kostomitsopoulos, N.G., Papageorgiou, E.G., Papassideri, I.S., Stamoulis, K., Kriebardis, A.G., Rinalducci, S., Antonelou, M.H.: Supplementation with uric and ascorbic acid protects stored red blood cells through enhancement of non-enzymatic antioxidant activity and metabolic rewiring. *Redox Biol.* 57, 102477 (2022). <https://doi.org/10.1016/j.redox.2022.102477>
28. Liu, X., Zhou, M., Wu, Y., Gao, X., Zhai, L., Liu, L., Geng, H.: Erythropoietin regulates osteoclast formation via up-regulating PPAR γ expression. *Mol. Med.* 30, 151 (2024). <https://doi.org/10.1186/s10020-024-00931-7>
29. Imam, M.U., Zhang, S., Ma, J., Wang, H., Wang, F.: Antioxidants Mediate Both Iron Homeostasis and Oxidative Stress. *Nutrients*. 9, 671 (2017). <https://doi.org/10.3390/nu9070671>
30. Alum, E.U., Aja, W., Ugwu, O.P.C., Obeagu, E.I., Okon, M.B.: Assessment of Vitamin Composition of Ethanol Leaf and Seed Extracts of *Datura Stramonium*. *Avicenna J. Med. Biochem.* 11, 92–97 (2023). <https://doi.org/10.34172/ajmb.2023.2421>
31. Shafras, M., Sabaragamuwa, R., Suwair, M.: Role of dietary antioxidants in diabetes: An overview. *Food Chem. Adv.* 4, 100666 (2024). <https://doi.org/10.1016/j.focha.2024.100666>
32. Li, N., Zhao, G., Wu, W., Zhang, M., Liu, W., Chen, Q., Wang, X.: The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia. *JAMA Netw. Open.* 3, e2023644 (2020). <https://doi.org/10.1001/jamanetworkopen.2020.23644>
33. Kilcarslan You, D., Fuwad, A., Lee, K.H., Kim, H.K., Kang, L., Kim, S.M., Jeon, T.-J.: Evaluation of the Protective Role of Vitamin E against ROS-Driven Lipid Oxidation in Model Cell Membranes. *Antioxidants*. 13, 1135 (2024). <https://doi.org/10.3390/antiox13091135>
34. Intharuksa, A., Kuljarusnont, S., Sasaki, Y., Tungmunthum, D.: Flavonoids and Other Polyphenols: Bioactive Molecules from Traditional Medicine Recipes/Medicinal Plants and Their Potential for Phytopharmaceutical and Medical Application. *Molecules*. 29, 5760 (2024). <https://doi.org/10.3390/molecules29235760>
35. Song, Y., Cook, N.R., Albert, C.M., Van Denburgh, M., Manson, J.E.: Effects of vitamins C and E and β -carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. *Am. J. Clin. Nutr.* 90, 429–437 (2009). <https://doi.org/10.3945/ajcn.2009.27491>
36. Krawczyk, M., Burzynska-Pedziwiatr, I., Wozniak, L.A., Bukowiecka-Matusiak, M.: Impact of Polyphenols on Inflammatory and Oxidative Stress Factors in Diabetes Mellitus: Nutritional Antioxidants and Their Application in Improving Antidiabetic Therapy. *Biomolecules*. 13, 1402 (2023). <https://doi.org/10.3390/biom13091402>
37. Samimi, F., Namiranian, N., Sharifi-Rigi, A., Siri, M., Abazari, O., Dastghaib, S.: Coenzyme Q10: A Key Antioxidant in the Management of Diabetes-Induced Cardiovascular Complications—An Overview of Mechanisms and Clinical Evidence. *Int. J. Endocrinol.* 2024, 2247748 (2024). <https://doi.org/10.1155/2024/2247748>
38. Aja PM, IO Igwenyi, PU Okechukwu, OU Orji, EU Alum. Evaluation of anti-diabetic effect and liver function indices of ethanol extracts of *Moringa oleifera* and *Cajanus cajan* leaves in alloxan induced diabetic albino rats *Global Veterinaria* 14(3) 439-447 (2015).
39. Offor CE, OPC Ugwu, EU Alum. The anti-diabetic effect of ethanol leaf-extract of *Allium sativum* on Albino rats. *International Journal of Pharmacy and Medical Sciences*, 4, (1), 01-03 (2014).
40. Enechi OC, H Ikenna Oluka, PC Okechukwu Ugwu. Acute toxicity, lipid peroxidation and ameliorative properties of *Alstonia boonei* ethanol leaf extract on the kidney markers of alloxan induced diabetic rats. *African journal of biotechnology*, 13, 5 (2014).
41. Adonu CC, OP Ugwu, A Bawa, EC Ossai, AC Nwaka. Intrinsic blood coagulation studies in patients suffering from both diabetes and hypertension. *Int Journal of Pharmaceutical Medicine and Bio Science*, 2 (2), 36-45 (2013).
42. Okechukwu Paul-Chima Ugwu, Esther Ugo Alum, Michael Ben Okon, Patrick M Aja, Emmanuel Ifeanyi Obeagu, EC Onyeneke Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats *Oxford University Press* 2(2) 10 (2023).

43. Mariam Oyedeggi Amusa and Adeyinka Olufemi Adepoju Okechukwu P. C. Ugwu, Esther Ugo Alum, Emmanuel I. Obeagu, Michael Ben Okon, Patrick M. Aja , Awotunde Oluwasegun Samson Effect of Ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin induced diabetic wistar albino rats. *IAA Journal of Biological Sciences*, 10, (1), 109-117 (2023).
44. Alum EU, GU Umoru, DE Uti, PM Aja, OP Ugwu, OU Orji, BU Nwali, NN Ezeani, N Edwin, FO Orinya HEPATO-PROTECTIVE EFFECT OF ETHANOL LEAF EXTRACT OF *Datura stramonium* in ALLOXAN-INDUCED DIABETIC ALBINO RATS. *Journal of Chemical Society of Nigeria*, 47, 5 (2022).
45. Ugwu Okechukwu P.C. and Amasiorah V.I. The effects of the crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on hematological indices and glycosylated haemoglobin of streptozotocin-induced diabetic. *INOSR Scientific Research*, 6, (1), 61-74 (2020).
46. Enechi OC, IH Oluka, OPC Ugwu, YS Omeh Effect of ethanol leaf extract of *Alstonia boonei* on the lipid profile of alloxan induced diabetic rats. *World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)*, 2013, Vol. 2, No. 3, 782-795(2012).

CITE AS: Nyiramana Mukamurera P. (2025). The Role of Antioxidants in Managing Diabetes-Associated Anemia: Current Evidence and Future Directions. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):86-92. <https://doi.org/10.59298/RIJSES/2025/528692>